Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Interest Expenses (2016 - 2025)

Historic Interest Expenses for BioCorRx (BICX) over the last 15 years, with Q3 2025 value amounting to $193431.0.

  • BioCorRx's Interest Expenses rose 2982.03% to $193431.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $445654.0, marking a year-over-year decrease of 3478.05%. This contributed to the annual value of $776780.0 for FY2024, which is 52142.4% up from last year.
  • Per BioCorRx's latest filing, its Interest Expenses stood at $193431.0 for Q3 2025, which was up 2982.03% from $36686.0 recorded in Q2 2025.
  • BioCorRx's Interest Expenses' 5-year high stood at $540435.0 during Q4 2021, with a 5-year trough of $4325.0 in Q3 2021.
  • Moreover, its 5-year median value for Interest Expenses was $100326.0 (2022), whereas its average is $121295.8.
  • As far as peak fluctuations go, BioCorRx's Interest Expenses crashed by 9667.17% in 2021, and later skyrocketed by 105648.8% in 2024.
  • Over the past 5 years, BioCorRx's Interest Expenses (Quarter) stood at $540435.0 in 2021, then tumbled by 95.61% to $23743.0 in 2022, then skyrocketed by 45.68% to $34588.0 in 2023, then surged by 270.23% to $128054.0 in 2024, then surged by 51.05% to $193431.0 in 2025.
  • Its Interest Expenses stands at $193431.0 for Q3 2025, versus $36686.0 for Q2 2025 and $87483.0 for Q1 2025.